Instrument Inactif

Autres langues TearLab Corp Nasdaq

Actions

US8781932004

Equipement, fournitures et distribution médicale

Autres langues

23/07/24	Bausch + Lomb Corporation acquired TearLab Corporation from Accelmed Partners and other shareholders for approximately $24 million.
09/12/21	TearLab Corporation Announces Board Appointments
09/12/21	TearLab Corporation Appoints Adam Szaronos as Chief Executive Officer
09/11/21	Tearlab Corporation Appoints James V. Mazzo to the Company's Board of Directors
16/09/21	MellingMedical and TearLab Agreement Aims to Enhance Early Detection of Dry Eye Disease in American Veterans
28/07/20	TearLab Appoints Adam Szaronos as Chief Commercial Officer
09/07/20	TEARLAB CORP : Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits (form 8-K)
09/07/20	Accelmed Partners II, fund managed by Accelmed Fund (Accelmed Partners) completed the acquisition of TearLab Corporation.
09/07/20	TearLab Corporation to Seek Acquisitions
26/06/20	TearLab: 1Q Earnings Snapshot
26/06/20	Tearlab Corporation Reports Earnings Results for the First Quarter Ended March 31, 2020
26/06/20	TEARLAB : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. (form 10-Q)
08/06/20	TEARLAB : Entry into a Material Definitive Agreement (form 8-K/A)
29/05/20	TEARLAB CORP : Entry into a Material Definitive Agreement (form 8-K)
13/05/20	TEARLAB CORP : Submission of Matters to a Vote of Security Holders (form 8-K)
12/05/20	TEARLAB CORP : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)
11/05/20	TEARLAB CORP : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Financial Statements and Exhibits (form 8-K)
11/05/20	TearLab Corporation Announces Board Appointments
11/05/20	TEARLAB CORP : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement, Unregistered Sale of Equity Securities, Changes in Control or Registrant, Other Events, Financial Statements and Exhibits (form 8-K)
11/05/20	Tearlab Mulls Inorganic Growth Opportunities
11/05/20	TearLab : Announces Acquisition By Accelmed Partners And Related $25 Million Investment
11/05/20	TearLab Corporation announced that it expects to receive $25 million in funding from Accelmed Fund
11/05/20	Accelmed Partners II, fund managed by Accelmed Fund (Accelmed Partners) entered into term sheet to acquire TearLab Corporation for $0.74 million.
07/05/20	TEARLAB CORP : Other Events, Financial Statements and Exhibits (form 8-K)
07/05/20	TearLab Corporation Confirms Merger Discussions